Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7388843 | Value in Health | 2018 | 10 Pages |
Abstract
At a threshold of £20,000/QALY, RFA was the treatment with highest median rank for net benefit, with MOCA second, EVLA third, HL/S fourth, CAE fifth, and CONS and UGFS sixth. Further evidence on effectiveness and health-related quality of life for MOCA and CAE is needed. At current prices, CAE is not a cost-effective option because it is costlier but has not been shown to be more effective than other options.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
David PhD, Sarah BSc, MBBS, MRCS, Roshan BSc, MBBS, MRCS, Marta PhD, Alun H. MA, DM, DSc, FRCS,